Latest Regulatory Approvals News

Dimerix’s latest PARASOL collaboration analysis reinforces proteinuria as a pivotal endpoint in their Phase 3 FSGS trial, setting the stage for FDA discussions on accelerated approval pathways.

EV Resources has entered a binding agreement to sell its Khartoum Project to Koba Resources for $700,000 cash plus a royalty, marking a strategic pivot towards its antimony assets and US critical minerals ambitions.

Mesoblast Limited reports a robust 66% increase in Ryoncil revenues for Q2 2025, driven by strong market adoption and new Medicare reimbursement codes.

Aumake Limited has launched Bio-Basic Ergothioneine, marking the debut of its innovative capital-light incubation model aimed at scaling premium health brands with minimal upfront investment.

Macro Metals Limited confirms key permitting milestones and advances offtake negotiations for its Extension Iron Ore Project, targeting construction readiness by late 2026.

Frontier Energy unveils an ambitious multi-stage expansion of its Waroona Renewable Energy Project, targeting 1GW of solar and 660MW of battery storage to support Western Australia’s coal phase-out.

Tombador Iron Limited, soon to be Atomic Eagle Limited, is set to acquire Canadian uranium explorer GoviEx Uranium Inc and relist on the ASX, backed by a $5–10 million capital raise to advance its flagship Muntanga Uranium Project in Zambia.

Snow Lake Resources is set to acquire Global Uranium, creating a leading U.S.-focused uranium developer with a diversified portfolio and enhanced market presence. The merger promises scale, strategic synergies, and exposure to critical nuclear fuel cycle technologies amid supportive U.S. policies.

Global Uranium and Snow Lake Resources have agreed to merge, creating a leading U.S.-focused uranium company valued at A$44.5 million. The deal consolidates key assets and promises enhanced exploration and development opportunities.

MAC Copper Limited has outlined the final timetable for its acquisition by Harmony Gold, including key dates for court approval, trading suspension, and shareholder payments.

The U.S. FDA has lifted the clinical hold on Neurizon Therapeutics’ lead drug candidate NUZ-001, enabling its entry into a major ALS platform trial set for Q4 2025. This regulatory milestone accelerates the company’s clinical development and opens doors for broader neurodegenerative applications.

Pioneer Lithium refines its exploration focus, prioritizing its US uranium projects with Skull Creek nearing drill readiness, while withdrawing from a Namibian uranium asset to optimize capital and value creation.